Therapies for coronaviruses. Part I of II -- viral entry inhibitors.
Identifieur interne : 002991 ( Main/Exploration ); précédent : 002990; suivant : 002992Therapies for coronaviruses. Part I of II -- viral entry inhibitors.
Auteurs : Tommy R. Tong [États-Unis]Source :
- Expert opinion on therapeutic patents [ 1744-7674 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Brevets comme sujet, Conception de médicament, Coronavirus (), Humains, Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Pénétration virale (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS ().
- MESH :
- pharmacologie : Antiviraux.
- traitement médicamenteux : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- virologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Animaux, Brevets comme sujet, Conception de médicament, Coronavirus, Humains, Pénétration virale, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Coronavirus (drug effects), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Drug Design, Humans, Patents as Topic, SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Virus Internalization (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : Coronavirus, SARS Virus, Virus Internalization.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Animals, Drug Design, Humans, Patents as Topic.
Abstract
Severe acute respiratory syndrome (SARS) coronavirus emerged fleetingly in the winter of 2002 and again in the winter of 2003, resulting in the infection of ~8,000 people and the death of ~800. The identification of the putative natural reservoir suggests that a re-emergence is possible. The functions of many coronaviral proteins have now been elucidated, resulting in many novel approaches to therapy.
DOI: 10.1517/13543770802609384
PubMed: 19449500
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001897
- to stream PubMed, to step Curation: 001897
- to stream PubMed, to step Checkpoint: 001755
- to stream Ncbi, to step Merge: 001F22
- to stream Ncbi, to step Curation: 001F22
- to stream Ncbi, to step Checkpoint: 001F22
- to stream Main, to step Merge: 002A32
- to stream Main, to step Curation: 002991
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapies for coronaviruses. Part I of II -- viral entry inhibitors.</title><author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name><affiliation wicri:level="2"><nlm:affiliation>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, Bronx, NY 10461, USA. ttong@montefiore.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, Bronx, NY 10461</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19449500</idno><idno type="pmid">19449500</idno><idno type="doi">10.1517/13543770802609384</idno><idno type="wicri:Area/PubMed/Corpus">001897</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001897</idno><idno type="wicri:Area/PubMed/Curation">001897</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001897</idno><idno type="wicri:Area/PubMed/Checkpoint">001755</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001755</idno><idno type="wicri:Area/Ncbi/Merge">001F22</idno><idno type="wicri:Area/Ncbi/Curation">001F22</idno><idno type="wicri:Area/Ncbi/Checkpoint">001F22</idno><idno type="wicri:Area/Main/Merge">002A32</idno><idno type="wicri:Area/Main/Curation">002991</idno><idno type="wicri:Area/Main/Exploration">002991</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapies for coronaviruses. Part I of II -- viral entry inhibitors.</title><author><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name><affiliation wicri:level="2"><nlm:affiliation>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, Bronx, NY 10461, USA. ttong@montefiore.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Jack D Weiler Hospital, Montefiore Medical Center, Department of Pathology, Bronx, NY 10461</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic patents</title><idno type="eISSN">1744-7674</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Coronavirus (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Drug Design</term><term>Humans</term><term>Patents as Topic</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Virus Internalization (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Brevets comme sujet</term><term>Conception de médicament</term><term>Coronavirus ()</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Pénétration virale ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>SARS Virus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Design</term><term>Humans</term><term>Patents as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Brevets comme sujet</term><term>Conception de médicament</term><term>Coronavirus</term><term>Humains</term><term>Pénétration virale</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus emerged fleetingly in the winter of 2002 and again in the winter of 2003, resulting in the infection of ~8,000 people and the death of ~800. The identification of the putative natural reservoir suggests that a re-emergence is possible. The functions of many coronaviral proteins have now been elucidated, resulting in many novel approaches to therapy.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Tong, Tommy R" sort="Tong, Tommy R" uniqKey="Tong T" first="Tommy R" last="Tong">Tommy R. Tong</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002991 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002991 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19449500
|texte= Therapies for coronaviruses. Part I of II -- viral entry inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19449500" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |